Anti CD19/BCMA CAR Gene Therapy for Autoimmune Diseases
NCT07121777 · Autoimmune Diseases
RecruitingThis is an open label, single-site, dose-escalation study in up to 18 participants with treatment of Refractory Autoimmune Diseases. This study aims to evaluate the safety and efficacy of the treatment with an Anti- CD19/BCMA CAR gene vector injection
PhaseNA
TypeInterventional
Age18 Years
WhereHefei, Anhui, China
SponsorAnhui Provincial Hospital
▾Tap for detailsClick for full details — eligibility, all locations, contacts Predictive Utility of a Short-term Improvement in Objectively Measured Physical Activity in Rheumatoid Arthritis (PUSIPA)
NCT06289114 ·
Rheumatoid Arthritis, Fibromyalgia, Secondary, Fatigue
RecruitingSUMMARY Background: Several studies have shown physical activity (PA) to be inversely correlated to disease activity in rheumatoid arthritis (RA) patients. However, it is unclear whether improved PA leads to lower disease activity or if low disease activity predicts improved PA in rheumatoid arthritis patients. Furthermore, it is unknown how fibromyalgia (FM) affects this interaction. Objective(s): Our primary objective will be to compare the effect of an immediate improvement in physical activity after one week on the proportion of RA patients achieving low disease activity after 12 weeks of biological treatment. Furthermore, we will explore whether the presence of concomitant FM affects this clinical response (i.e., interaction between FM status and PA response). Design: A prospective cohort study in the form of a target-trial attempting to address a causal question comparing the outcome among the participants with an immediate improvement in physical activity, relative to individuals without. Setting and patients: Biologically naive RA patients initiating biological treatment are consecutively enrolled. PA is quantified by accelerometry one week prior to, one week after, and after 3 months of biological treatment. Sample size: 100 RA patients starting biological therapy is planned enrolled in the study. Measurements: RA patients will be divided into two groups depending on their improvement in physical activity after onset of biological treatment. The percentage of time spent in moderate-to-vigorously physical activity (MVPA) i.e., the percentage of time a patient is in motion \[walking, running, bicycling, or swimming\] is measured prior to, one week, and approximately 3 months after biological treatment onset, respectively. The MVPA ratio (MVPA After biological treatment/MVPA Before biological treatment) will divide patients enabling a contrast between two groups: Those with high improvement considering MVPA (after 1 week; the upper tertile of MVPA ratio of the sample) and those without. Treatment response (achieving a disease activity score \< 3.2) after approximately 3 months from baseline will be analyzed as the contrast between groups.
Phase—
TypeObservational
Age18 Years
WhereEsbjerg, Denmark
SponsorEsbjerg Hospital - University Hospital of Southern Denmark
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Phase IIa Study of JAB-8263 in Patients With Active Rheumatoid Arthritis
RecruitingThis study is an open-label, multi-center Phase IIa study. The study is divided into two phases. The first phase is a safety exploration phase. Participants with active rheumatoid arthritis were enrolled and treated with JAB-8263 alone for 4 weeks. The purpose is to evaluate the safety, PK/PD characteristics and preliminary effectiveness of JAB-8263 in participants with active RA.
PhasePhase 2
TypeInterventional
Age18 Years – 75 Years
WhereBeijing, Beijing Municipality, China
SponsorJacobio Pharmaceuticals Co., Ltd.
▾Tap for detailsClick for full details — eligibility, all locations, contacts Rheumatoid Arthritis Remission Screening and Prospective Surveillance
RecruitingHARMONICS is a prospective registry embedded in the routine clinical practice of the Early Arthritis Clinic and the Prospective Remission Clinic at Fondazione IRCCS Policlinico San Matteo, with an associated research biorepository of voluntarily donated biological samples. It is designed to collect and generate long-term longitudinal data from patients with early-treated rheumatoid arthritis (RA) who have achieved stable clinical remission with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and undergo treatment tapering or discontinuation according to local care pathways, following shared decision-making between the patient and the treating rheumatologist. Following enrollment in stable clinical remission, patients are monitored as part of standard of care at regular intervals using clinical, ultrasound, and radiographic assessments to evaluate disease activity and outcomes. Treatment modifications, including tapering, discontinuation, and re-treatment, are recorded longitudinally. Participants are followed in the registry from enrollment for up to 60 months, unless a disease flare occurs earlier. Patients experiencing a disease flare within the initial 60-month follow-up period undergo an additional 12 months of follow-up after flare. The registry aims to provide a comprehensive longitudinal framework of multimodal data to advance the clinical and pathophysiological understanding of remission phenotypes and natural disease trajectories, with the ultimate goals of: * optimizing risk stratification and therapeutic decision-making in patients with RA in remission; and * identifying and exploring novel targets for potential transformative therapies.
Phase—
TypeObservational
Age18 Years
WherePavia, Pavia, Italy
SponsorFondazione IRCCS Policlinico San Matteo di Pavia
▾Tap for detailsClick for full details — eligibility, all locations, contacts IMPACT - AndHealth Autoimmune Research Registry
NCT05883371 · Arthritis, Rheumatoid, Arthritis, Psoriatic,
Psoriasis RecruitingThis is a patient research registry aimed at evaluating the effectiveness of a comprehensive, root-cause medical approach ("AndHealth program") for autoimmune disorders. This approach involves a combination of pharmacological and non-pharmacological therapies offered under the care of a licensed physician with the support of health coaches. While protocol guidance is provided, the therapeutic approach is personalized to the individual needs of patients. The autoimmune disorders of focus in this registry include rheumatoid arthritis, psoriatic arthritis, psoriasis and ankylosing spondylitis. A variety of validated labs, patient-reported outcomes, and medication usage will be assessed among participating patients over a period of up to five years to evaluate the long-term effectiveness of this approach.
Phase—
TypeObservational
Age18 Years – 70 Years
WhereColumbus, Ohio, United States
SponsorAndHealth
▾Tap for detailsClick for full details — eligibility, all locations, contacts Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease
NCT06397677 ·
Rheumatoid Arthritis, Interstitial Lung Disease
RecruitingA study to identify patients with Rheumatoid Arthritis - Associated Interstitial Lung Disease (RA-ILD) that are at the highest risk for progression. The goal of the investigators is to recruit a group of patients with RA-ILD and collect information to help us understand more about disease progression. The investigators will do this using a combination of clinical, radiologic, and biologic features.
Phase—
TypeObservational
Age18 Years – 90 Years
WhereSan Francisco, California, United States + 3 more
SponsorUniversity of Colorado, Denver
▾Tap for detailsClick for full details — eligibility, all locations, contacts Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
NCT07404865 · Primary Sjogren's Disease
RecruitingPhase 3 Study of Telitacicept in Active Primary Sjögren's Disease (UPSTREAM SjD)
PhasePhase 3
TypeInterventional
Age18 Years – 75 Years
WhereChandler, Arizona, United States + 48 more
SponsorVor Biopharma
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Comparison Study of Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world SettING
RecruitingThis study will compare the retention rates for UPA vs. TNFi treatment in adult participants with moderate to severe active RA per local label and according to local standard of care This is a mono-country, prospective, multi-center observational study in patients with moderate to severe active RA receiving UPA or TNFi therapy. Around 678 participants will be enrolled in approximately 80 sites in Germany. Study recruitment will last approximately 24 months, and the study participation time will be up to 24 months, for a total study duration of approximately 48 months.
Phase—
TypeObservational
Age18 Years
WhereFreiburg im Breisgau, Baden-Wurttemberg, Germany + 75 more
SponsorAbbVie
▾Tap for detailsClick for full details — eligibility, all locations, contacts "Translating Articular Biomarkers Into Diagnoses"
NCT06312943 · Inflammatory and Non-inflammatory Bone and Joint Diseases
RecruitingEarly diagnosis is a key factor in the prevention and management of rheumatic diseases. Rheumatic diseases are classically diagnosed based on criteria combining clinical, biological and radiological features. However, in up to 20% of the cases, diagnoses remain unstated and underlying rheumatic diseases unclassified, which might lead to delayed specific treatment and unfavourable clinical outcomes. In addition, conventional methods could lack sensitivity and specificity for early diagnosis. Biological samples are attractive targets for the early detection of articular damage because they allow for collection of multiple levels of information from the clinic and the laboratory\]. Biological samples most frequently collected from patients with rheumatic diseases are synovial fluid by joint aspiration, blood by venous puncture and tissue specimen by surgery. The investigators hypothesize that in challenging situations, novel biomarkers detected from synovial fluid or articular tissues using both conventional (e.g. histology, immunodetection, PCR) and innovative (e.g. Raman spectroscopy, nanospectroscopy) laboratory tests may help refining diagnosis and better classifying patients with rheumatic diseases.
Phase—
TypeObservational
Age18 Years
WhereParis, IDF, France
SponsorAssistance Publique - Hôpitaux de Paris
▾Tap for detailsClick for full details — eligibility, all locations, contacts MTS109 in Patients With Refractory Autoimmune Diseases
NCT07526350 ·
Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Systemic Sclerosis (SSc)
RecruitingThis is the first-in-human trial of MTS109 (mRNA-LNP). The goal of this clinical trial is to evaluate the safety, tolerability of intravenous injection of MTS109 in moderate to severe autoimmune diseases.
PhaseEARLY_Phase 1
TypeInterventional
Age18 Years – 65 Years
WhereShanghai, Shanghai Municipality, China
SponsorShanghai Changzheng Hospital
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases
RecruitingThis is an open-label, multi-ascending dose (MAD) phase 1 study, with dose expansion at selected doses, in adult patients with select autoimmune rheumatic diseases including systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA). The purpose of the study is to identify possible optimal dose(s) by assessing the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and preliminary clinical response of SAR448501/DR-0201. The study duration per participant will be a minimum of approximately 13 months, including a screening period of up to 28 days, a treatment period of 71 days, and a follow-up period of 42 weeks. If necessary, participants will continue to have visits after End of Study (EOS) every 4 weeks until peripheral blood B cells return to at least 80% of either the lower limit of normal (LLN) or the participant's baseline value.
PhasePhase 1
TypeInterventional
Age18 Years – 75 Years
WhereMelbourne, Victoria, Australia + 7 more
SponsorSanofi
▾Tap for detailsClick for full details — eligibility, all locations, contacts Nicorandil as Anti-inflammatory in Rheumatoid Arthritis
NCT07516769 · Rhumatoid Arthisis
RecruitingThis study aims to evaluate the possible efficacy and safety of nicorandil as anti-inflammatory in managing patients with active rheumatoid arthritis.
PhasePhase 3
TypeInterventional
Age18 Years – 70 Years
WhereTanta, Gharbia Governorate, Egypt
SponsorTanta University
▾Tap for detailsClick for full details — eligibility, all locations, contacts Belimumab After Rituximab in Resistant Primary Juvenile SS
NCT06410833 · Sjogren's Syndrome, Pediatric ALL
RecruitingThe goal of this clinical trial is to explore the effectiveness of sequential use of rituximab and belimumab in the treatment of resistant primary juvenile Sjogren's syndrome. Does sequential use of rituximab and belimumab reduce the activity of SS in resistant patients Researchers will compare the disease activity before and after the treatment of sequential use of rituximab and belimumab to see if the therapy works to treat SS. Participants will: Recieve Rituximab each week for 2-4 times until B%\<0.5% or B#\<20×10\^6/L Recieve Belimumab 4 weeks after the last use of Rituximab, and then every 4 weeks until week 28
PhasePhase 4
TypeInterventional
Age5 Years – 18 Years
WhereBeijing, Beijing Municipality, China
SponsorPeking Union Medical College Hospital
▾Tap for detailsClick for full details — eligibility, all locations, contacts The Clinical Study on the Treatment of Refractory RA With UTAA91 Injection
RecruitingThis clinical trial is designed as a single - arm, open - label, single - center, investigator - initiated early - phase clinical study. The primary objective is to evaluate the safety of UTAA91 injection in treating subjects with refractory moderate - to - severe active rheumatoid arthritis.
PhaseEARLY_Phase 1
TypeInterventional
Age18 Years
WhereWuhan, Hubei, China
SponsorUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
▾Tap for detailsClick for full details — eligibility, all locations, contacts Interferon Signature in Anti-CTLA-4 and Anti-PD-1/PD-L1-Treated Cancer Patients Compared With Systemic Autoimmune Disease Patients
NCT07249060 · Immune-Related Adverse Events,
Lupus Erythematosus, Systemic, Sjogren Syndrome
RecruitingThis study aims to identify a way to predict the side effects that some people with cancer experience when receiving immunotherapy. These side effects, known as immune-related adverse events (irAEs), occur when the immune system mistakenly attacks healthy tissues, like certain autoimmune diseases. At present, clinicians lack reliable tests to determine who is most likely to develop these reactions. The goal of this study is to determine whether substances in the blood called interferons (IFNs) could serve as early warning markers. The study will include 300 people with cancer who are about to begin immunotherapy. To provide a meaningful comparison, the investigators will also enroll 40 individuals with autoimmune diseases such as lupus. Understanding how IFN levels differ between these groups may help clarify whether IFN patterns in cancer patients resemble those seen in autoimmune disease. Participants in both groups will be asked to provide small blood samples at predefined time points during their clinical care or treatment. Researchers will measure the levels of different IFN types in all samples to compare IFN levels between cancer patients and individuals with autoimmune diseases, and within the cancer group between patients who develop irAEs and those who do not. The long-term aim of the study is to develop a simple test that can help clinicians identify patients at higher risk of irAEs. Immune-related adverse events (irAEs) are a frequent complication in cancer patients treated with immune checkpoint inhibitors (ICIs), and they often resemble or exacerbate preexisting autoimmune diseases. Despite extensive research in the field, no validated predictive biomarkers of irAEs currently exist. Emerging evidence suggests that the IFN signature -long implicated in the pathogenesis of several systemic autoimmune diseases (SADs)- may also be upregulated in patients who develop ICI-induced irAEs, likely with substantial overlap among different IFN subtypes. Given these clinical and molecular similarities with SADs, it is plausible that IFN levels in peripheral blood carry predictive value for irAE risk, although the dominant IFN types in ICI-related toxicity remain unknown. The INTER-AUTENTIC project aims to determine whether baseline IFN levels and their dynamic changes, measured in peripheral blood using a dedicated panel, can predict the onset of irAEs in cancer patients receiving ICIs. Supported by the Medical Oncology departments of six university hospitals in Northern Spain, this multicenter, observational, prospective cohort study has been underway since 2021. Biobank samples have been collected from ICI-treated patients before treatment initiation, at protocol-defined time points, and at the moment of irAE diagnosis (ICI cohort). The study seeks to identify the IFN subtypes with the most pronounced differential expression between patients with and without irAEs, and to evaluate whether IFN levels enhance the predictive performance of a model incorporating other clinical variables potentially associated with immune-mediated toxicity. A sample size of 300 cancer patients has been estimated for this analysis. In addition, a second prospective cohort of 40 non-cancer patients with systemic lupus erythematosus, primary Sjögren's syndrome, systemic sclerosis, and/or idiopathic inflammatory myopathy (SAD cohort) will be included. Since IFNs play a well-established pathogenic role in these conditions, this cohort will allow characterization of the IFN signature at key follow-up points (baseline, remission, and disease flare) and comparison with the IFN profiles of ICI-treated patients, regardless of whether they develop irAEs.
Phase—
TypeObservational
Age18 Years
WherePamplona, Navarre, Spain
SponsorHospital Universitario Araba
▾Tap for detailsClick for full details — eligibility, all locations, contacts Effect of Roflumilast and Desloratadine as Add-On Therapy in Patients With Rheumatoid Arthritis
RecruitingRheumatoid arthritis is a chronic inflammatory disease that causes joint pain, swelling, and disability. Although standard disease-modifying antirheumatic drugs (DMARDs) are effective for many patients, some individuals continue to experience active disease and inflammation. The aim of this study is to evaluate the effectiveness and safety of adding either roflumilast or desloratadine to standard DMARD therapy in patients with rheumatoid arthritis. Participants will be randomly assigned to receive either roflumilast, desloratadine, or placebo in addition to their usual treatment. The study will assess changes in disease activity, inflammatory biomarkers, and patient-reported outcomes over a three-month follow-up period. The results of this study may help identify new add-on treatment options to improve disease control in patients with rheumatoid arthritis.
PhasePhase 2
TypeInterventional
Age18 Years – 60 Years
WhereDamietta, Damietta Governorate, Egypt
SponsorHorus University
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic
NCT07123038 ·
Rheumatoid Arthritis (RA), Hidradenitis Suppurativa (HS)
RecruitingTo assess the emergence, type, severity, and potential causality of delayed adverse events following administration of a gene-modified Treg therapeutic.
Phase—
TypeObservational
Age18 Years – 71 Years
WhereSan Francisco, California, United States + 9 more
SponsorSonoma Biotherapeutics, Inc.
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis
RecruitingThe purpose of this study is to evaluate how well LY4213663 is tolerated and what side effects may occur in healthy participants and participants with rheumatoid arthritis (RA). The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last approximately 33 weeks excluding screening.
PhasePhase 1
TypeInterventional
Age18 Years – 75 Years
WhereAnniston, Alabama, United States + 9 more
SponsorEli Lilly and Company
▾Tap for detailsClick for full details — eligibility, all locations, contacts Pain Processing in Inflammatory and Non-Inflammatory Chronic Pain Syndromes
NCT05277025 · Fibromyalgia,
Rheumatoid Arthritis RecruitingFibromyalgia (FM) is a chronic musculoskeletal pain disorder that afflicts up to 4% of the general population. The evaluation of pain mechanisms in FM has shown predominant central abnormalities and therefore has been designated as nociplastic pain syndrome. Rheumatoid arthritis (RA) is characterized by polyarthritis and pain from inflamed tissues, consistent with nociceptive pain. FM and RA patients may utilize overlapping pain mechanisms resulting in nociceptive and nociplastic pain.
Phase—
TypeObservational
Age18 Years – 70 Years
WhereGainesville, Florida, United States
SponsorUniversity of Florida
▾Tap for detailsClick for full details — eligibility, all locations, contacts Clinical Cohort Construction and Therapeutic Effect Evaluation of Integrated Traditional Chinese and Western Medicine in the Treatment of Rheumatoid Arthritis
RecruitingThis is a large-scale, multicenter observational study on the treatment of rheumatoid arthritis (RA) with integrated Traditional Chinese and Western medicine. The study plans to enroll at least 10,000 patients, including a minimum of 1,000 cases with difficult-to-treat RA (D2T RA) and 1,000 cases with RA-associated interstitial lung disease (RA-ILD). Through long-term follow-up, data will be collected on Traditional Chinese Medicine (TCM) syndrome characteristics, treatment plans, adverse drug reactions, and complications. Biological samples, including blood and urine, will also be collected. The research will utilize multi-omics technologies such as genomics and proteomics, combined with clinical data, to deeply explore the modern scientific connotation of the "disease-syndrome-symptom" framework in RA. The goal is to clarify the patterns and advantages of TCM syndrome differentiation and treatment. Based on these findings, a scientific and standardized efficacy evaluation system for integrated treatment will be established, and optimized treatment strategies for D2T RA and RA-ILD will be developed. The project is led by multiple national TCM clinical research centers and regional diagnostic and treatment centers, including the First Teaching Hospital of Tianjin University of TCM and Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine. These institutions have mature clinical research platforms, biobanks, and databases, providing a solid foundation for the successful implementation of this study. The results of this research will provide a scientific basis for the integrated treatment of RA, promote the standardization of diagnostic and treatment protocols, and ultimately improve the overall level of RA prevention and treatment in China.
Phase—
TypeObservational
Age18 Years
WhereShanghai, China
SponsorDongyi He
▾Tap for detailsClick for full details — eligibility, all locations, contacts